Advanced

Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.

Jerkeman, Mats LU ; Aman, P; Cavallin-Ståhl, Eva LU ; Torlakovic, E; Åkerman, Måns LU ; Mitelman, Felix LU and Fioretos, Thoas LU (2002) In International Journal of Oncology 20(1). p.161-165
Abstract
The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase... (More)
The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Gene Rearrangement B-Lymphocyte : genetics, Human, Immunophenotyping, Lymphoma B-Cell : drug therapy : genetics, Leucovorin : therapeutic use, Lactate Dehydrogenase : metabolism, Lymphoma Large-Cell Diffuse : drug therapy : genetics, Male, Methotrexate : therapeutic use, Middle Age, Neoplasm Staging, Prednisone : therapeutic use, Prognosis, Proto-Oncogene Proteins : genetics, Support Non-U.S. Gov't, Vincristine : therapeutic use, Transcription Factors : genetics, Doxorubicin : therapeutic use, DNA-Binding Proteins : genetics, DNA Neoplasm : analysis : metabolism, Cyclophosphamide : therapeutic use, Blotting Southern, Bleomycin : therapeutic use, Antineoplastic Combined Chemotherapy Protocols : therapeutic use, Aged, Adolescence, Adult
in
International Journal of Oncology
volume
20
issue
1
pages
161 - 165
publisher
D.A. Spandidos
external identifiers
  • wos:000172916500023
  • pmid:11743658
  • scopus:0036133890
ISSN
1019-6439
language
English
LU publication?
yes
id
dd3c1cf3-397d-4d51-9756-a22b261e6272 (old id 107004)
alternative location
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11743658
http://147.52.72.117/IJO/2002/volume20/number1/161-165.pdf
date added to LUP
2007-07-18 16:40:50
date last changed
2017-01-01 06:43:06
@article{dd3c1cf3-397d-4d51-9756-a22b261e6272,
  abstract     = {The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables.},
  author       = {Jerkeman, Mats and Aman, P and Cavallin-Ståhl, Eva and Torlakovic, E and Åkerman, Måns and Mitelman, Felix and Fioretos, Thoas},
  issn         = {1019-6439},
  keyword      = {Gene Rearrangement B-Lymphocyte : genetics,Human,Immunophenotyping,Lymphoma B-Cell : drug therapy : genetics,Leucovorin : therapeutic use,Lactate Dehydrogenase : metabolism,Lymphoma Large-Cell Diffuse : drug therapy : genetics,Male,Methotrexate : therapeutic use,Middle Age,Neoplasm Staging,Prednisone : therapeutic use,Prognosis,Proto-Oncogene Proteins : genetics,Support Non-U.S. Gov't,Vincristine : therapeutic use,Transcription Factors : genetics,Doxorubicin : therapeutic use,DNA-Binding Proteins : genetics,DNA Neoplasm : analysis : metabolism,Cyclophosphamide : therapeutic use,Blotting Southern,Bleomycin : therapeutic use,Antineoplastic Combined Chemotherapy Protocols : therapeutic use,Aged,Adolescence,Adult},
  language     = {eng},
  number       = {1},
  pages        = {161--165},
  publisher    = {D.A. Spandidos},
  series       = {International Journal of Oncology},
  title        = {Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.},
  volume       = {20},
  year         = {2002},
}